You've really got to hand it to all those 15-minute oil change places that dot the American landscape: they know how to pull motorists in.
With their brightly colored signs and endless promotions, it’s no wonder they succeed in getting our business. Whether you’re driving a brand new sports car or sedan with 200,000 miles on it, you’re welcome to drive up, get fresh oil and drive away...no problem.
But when it comes to bone marrow transplants, the sobering fact is that the age of the vehicle —in this case, your body — does matter.
Bone marrow transplants are one of the few long-term effective treatments for blood cancers such as acute myeloid leukemia (AML). Most blood cancer patients are over age 55 and the proportion is increasing, but many in this group who need a transplant are ruled ineligible for the procedure. Why? Because the high-dose chemotherapy needed to prepare the patient for the transplant is often deemed too harsh for them.
Since more than two-thirds of AML patients are more than 55 years old, new tactics are desperately needed. What if a patient’s diseased bone marrow could be eradicated prior to the transplant without the need for high-dose chemo and high doses of external radiation?
This approach is being pursued by Actinium Pharmaceuticals, Inc. (disclosure - I run the company) and our lead compound, called Iomab™-B, has already been deployed in clinical trials for incurable blood cancers like AML with encouraging results. It has shown the ability to prepare such patients for bone marrow transplants when no other treatments were feasible.
Iomab™-B exploits an approach known as radioimmunotherapy, which combines two cancer-fighting agents: large proteins (called monoclonal antibodies or mAbs) that bind to cancer cells and attack them while largely sparing surrounding normal tissue, and cancer-killing radioisotopes that piggyback on the mAbs.
Credit and link:
Actinium Pharmaceuticals, Inc.
Treatment with Iomab™-B has shown in clinical studies that it does not produce the side effects associated with high-dose chemotherapy that can often be lethal to older patients. In addition, the compound is designed to prepare a patient for bone marrow transplant in only 10 days, compared to the four to six weeks required with traditional care—a potentially vital difference in the face of a fast-evolving cancer.
On the strength of results obtained to date, Actinium is will begin a pivotal clinical trial later this year.
A bone marrow transplant will never be as easy to undergo as an oil change. But if Actinium’s work bears fruit, one thing might someday be true for oil changes and bone marrow transplants alike: age won’t matter.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Researchers Created A Laser Bullet To See What It Would Look Like - And Here It Is
- The Strange Organic Molecules In Titan's Atmosphere
- Will Holding Thermal Printer Paper Really Send Your BPA Levels Soaring?
- The Quote Of The Week - Shocked And Disappointed
- As The Weather Changes, So Do Beliefs About Climate Change
- ECFA Workshop: Planning For The High Luminosity LHC
- Moderate Pot Use By Adolescents Doesn't Hurt IQ
- "Hi Nury, good to see you back here again after so many months away from this monster Science20..."
- "The OSX versions are all free, the all in one IOS version is not free. The developer (which I am..."
- "Anonymous, when you disagree, be civil and cite the specific sentence or quote that you disagree..."
- "I wonder how this one was genetically modified?(cartoon by Norman Thelwell) ..."
- "I have no time for you. Either learn how to have a decent, mature conversation without resorting..."
- Coffee grounds turned biofuel can heat your home
- Bill and Melinda Gates on GMOs: ‘Poor farmers should not be denied choice of life-saving tools’
- Why do foodies love organics? Because they taste like McDonald’s!
- GMO milk? An enviros dream innovation that most enviros oppose
- National Wildlife Refuge System bans on GMOs and neonics lack transparency, scientific rationale
- Want better sperm? Eat more pesticides
- New policymaking tool for shift to renewable energy
- Teens whose parents exert more psychological control have trouble with closeness, independence
- Two days later: Adolescents' conflicts with family spill over to school, vice versa
- Children in high-quality early childhood education are buffered from changes in family income
- 'Breath test' shows promise for diagnosing fungal pneumonia